An updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for melanoma

EORTC Melanoma Grp; Martin G. Cook; Daniela Massi; Anna Szumera-Cieckiewicz; Joost Van den Oord; Willeke Blokx; Leon C. van Kempen; Thiagarajah Balamurugan; Francesca Bosisio; Senada Koljenovic; Francesca Portelli; Alexander C. J. van Akkooi

doi:10.1016/j.ejca.2019.03.010

An updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for melanoma

EORTC Melanoma Grp, Martin G. Cook^*, Daniela Massi, Anna Szumera-Cieckiewicz, Joost Van den Oord, Willeke Blokx, Leon C. van Kempen, Thiagarajah Balamurugan, Francesca Bosisio, Senada Koljenovic, Francesca Portelli, Alexander C. J. van Akkooi

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

37 Citations (Scopus)

149 Downloads (Pure)

Abstract

The sentinel lymph node (SLN) biopsy is a highly accurate staging procedure and the most important prognostic factor in melanoma patients. The European Organisation for Research and Treatment of Cancer (EORTC) Melanoma Group aimed to design an updated evolved SLN protocol for the histopathological workup and reporting. We herein recommend extending the distance between steps according to the short axis dimension of the lymph node and optimise both conventional sectioning and staining procedures including immunohisto-chemistry. We also provide guidance on the description of the spatial localisation of melanoma deposits in a SLN. The histopathological features to be reported include the following: presence or absence of the metastasis, the intranodal location of the metastasis (subcapsular, parenchymal, combined, extensive confluent and extensive multifocal), the number of the metastatic deposits (1, 2-5, 6-10, 11-20 and > 20), the maximum dimension of the largest metastasis (indicating its site) and the presence of extracapsular extension and of naevus cells. This updated EORTC protocol is expected to clarify and simplify the existing procedures, ensuring a reasonable workload for the laboratory and for the pathologists resulting in cost saving with no loss, and possible increase, in accuracy. (C) 2019 Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	1-7
Number of pages	7
Journal	European Journal of Cancer
Volume	114
DOIs	https://doi.org/10.1016/j.ejca.2019.03.010
Publication status	Published - Jun-2019

Keywords

Melanoma
Sentinel lymph node
Pathology protocol
Sectioning
Tumour burden
Metastasis topography
Immunohis-tochemistry
Nodal naevus cells
Recommendations
MALIGNANT-MELANOMA
IMMUNOHISTOCHEMICAL EVALUATION
PROGNOSTIC-SIGNIFICANCE
METASTATIC MELANOMA
CUTANEOUS MELANOMA
CLINICAL-RELEVANCE
TUMOR BURDEN
SURVIVAL
MICROMETASTASES
INVOLVEMENT

Access to Document

10.1016/j.ejca.2019.03.010

An updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for melanomaFinal publisher's version, 2.67 MBLicence: Taverne

Handle.net

Persistent link

Cite this

EORTC Melanoma Grp, Cook, M. G., Massi, D., Szumera-Cieckiewicz, A., Van den Oord, J., Blokx, W., van Kempen, L. C., Balamurugan, T., Bosisio, F., Koljenovic, S., Portelli, F., & van Akkooi, A. C. J. (2019). An updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for melanoma. European Journal of Cancer, 114, 1-7. https://doi.org/10.1016/j.ejca.2019.03.010

@article{e031b6746b164f99aa413c4144dce728,

title = "An updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for melanoma",

abstract = "The sentinel lymph node (SLN) biopsy is a highly accurate staging procedure and the most important prognostic factor in melanoma patients. The European Organisation for Research and Treatment of Cancer (EORTC) Melanoma Group aimed to design an updated evolved SLN protocol for the histopathological workup and reporting. We herein recommend extending the distance between steps according to the short axis dimension of the lymph node and optimise both conventional sectioning and staining procedures including immunohisto-chemistry. We also provide guidance on the description of the spatial localisation of melanoma deposits in a SLN. The histopathological features to be reported include the following: presence or absence of the metastasis, the intranodal location of the metastasis (subcapsular, parenchymal, combined, extensive confluent and extensive multifocal), the number of the metastatic deposits (1, 2-5, 6-10, 11-20 and > 20), the maximum dimension of the largest metastasis (indicating its site) and the presence of extracapsular extension and of naevus cells. This updated EORTC protocol is expected to clarify and simplify the existing procedures, ensuring a reasonable workload for the laboratory and for the pathologists resulting in cost saving with no loss, and possible increase, in accuracy. (C) 2019 Elsevier Ltd. All rights reserved.",

keywords = "Melanoma, Sentinel lymph node, Pathology protocol, Sectioning, Tumour burden, Metastasis topography, Immunohis-tochemistry, Nodal naevus cells, Recommendations, MALIGNANT-MELANOMA, IMMUNOHISTOCHEMICAL EVALUATION, PROGNOSTIC-SIGNIFICANCE, METASTATIC MELANOMA, CUTANEOUS MELANOMA, CLINICAL-RELEVANCE, TUMOR BURDEN, SURVIVAL, MICROMETASTASES, INVOLVEMENT",

author = "{EORTC Melanoma Grp} and Cook, {Martin G.} and Daniela Massi and Anna Szumera-Cieckiewicz and {Van den Oord}, Joost and Willeke Blokx and {van Kempen}, {Leon C.} and Thiagarajah Balamurugan and Francesca Bosisio and Senada Koljenovic and Francesca Portelli and {van Akkooi}, {Alexander C. J.}",

year = "2019",

month = jun,

doi = "10.1016/j.ejca.2019.03.010",

language = "English",

volume = "114",

pages = "1--7",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "ELSEVIER SCI LTD",

}

EORTC Melanoma Grp, Cook, MG, Massi, D, Szumera-Cieckiewicz, A, Van den Oord, J, Blokx, W, van Kempen, LC, Balamurugan, T, Bosisio, F, Koljenovic, S, Portelli, F & van Akkooi, ACJ 2019, 'An updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for melanoma', European Journal of Cancer, vol. 114, pp. 1-7. https://doi.org/10.1016/j.ejca.2019.03.010

TY - JOUR

T1 - An updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for melanoma

AU - EORTC Melanoma Grp

AU - Cook, Martin G.

AU - Massi, Daniela

AU - Szumera-Cieckiewicz, Anna

AU - Van den Oord, Joost

AU - Blokx, Willeke

AU - van Kempen, Leon C.

AU - Balamurugan, Thiagarajah

AU - Bosisio, Francesca

AU - Koljenovic, Senada

AU - Portelli, Francesca

AU - van Akkooi, Alexander C. J.

PY - 2019/6

Y1 - 2019/6

N2 - The sentinel lymph node (SLN) biopsy is a highly accurate staging procedure and the most important prognostic factor in melanoma patients. The European Organisation for Research and Treatment of Cancer (EORTC) Melanoma Group aimed to design an updated evolved SLN protocol for the histopathological workup and reporting. We herein recommend extending the distance between steps according to the short axis dimension of the lymph node and optimise both conventional sectioning and staining procedures including immunohisto-chemistry. We also provide guidance on the description of the spatial localisation of melanoma deposits in a SLN. The histopathological features to be reported include the following: presence or absence of the metastasis, the intranodal location of the metastasis (subcapsular, parenchymal, combined, extensive confluent and extensive multifocal), the number of the metastatic deposits (1, 2-5, 6-10, 11-20 and > 20), the maximum dimension of the largest metastasis (indicating its site) and the presence of extracapsular extension and of naevus cells. This updated EORTC protocol is expected to clarify and simplify the existing procedures, ensuring a reasonable workload for the laboratory and for the pathologists resulting in cost saving with no loss, and possible increase, in accuracy. (C) 2019 Elsevier Ltd. All rights reserved.

AB - The sentinel lymph node (SLN) biopsy is a highly accurate staging procedure and the most important prognostic factor in melanoma patients. The European Organisation for Research and Treatment of Cancer (EORTC) Melanoma Group aimed to design an updated evolved SLN protocol for the histopathological workup and reporting. We herein recommend extending the distance between steps according to the short axis dimension of the lymph node and optimise both conventional sectioning and staining procedures including immunohisto-chemistry. We also provide guidance on the description of the spatial localisation of melanoma deposits in a SLN. The histopathological features to be reported include the following: presence or absence of the metastasis, the intranodal location of the metastasis (subcapsular, parenchymal, combined, extensive confluent and extensive multifocal), the number of the metastatic deposits (1, 2-5, 6-10, 11-20 and > 20), the maximum dimension of the largest metastasis (indicating its site) and the presence of extracapsular extension and of naevus cells. This updated EORTC protocol is expected to clarify and simplify the existing procedures, ensuring a reasonable workload for the laboratory and for the pathologists resulting in cost saving with no loss, and possible increase, in accuracy. (C) 2019 Elsevier Ltd. All rights reserved.

KW - Melanoma

KW - Sentinel lymph node

KW - Pathology protocol

KW - Sectioning

KW - Tumour burden

KW - Metastasis topography

KW - Immunohis-tochemistry

KW - Nodal naevus cells

KW - Recommendations

KW - MALIGNANT-MELANOMA

KW - IMMUNOHISTOCHEMICAL EVALUATION

KW - PROGNOSTIC-SIGNIFICANCE

KW - METASTATIC MELANOMA

KW - CUTANEOUS MELANOMA

KW - CLINICAL-RELEVANCE

KW - TUMOR BURDEN

KW - SURVIVAL

KW - MICROMETASTASES

KW - INVOLVEMENT

U2 - 10.1016/j.ejca.2019.03.010

DO - 10.1016/j.ejca.2019.03.010

M3 - Article

C2 - 31005015

SN - 0959-8049

VL - 114

SP - 1

EP - 7

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

An updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for melanoma

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this